Straits Times Index
3,301.41 -12.64 (-0.38%) Nikkei
39,165.01 +95.33 (+0.24%) Hang Seng
19,223.10 -413.12 (-2.10%) FTSE 100
8,424.20 +3.94 (+0.05%) Bitcoin USD
71,359.60 +4,677.13 (+7.01%) CMC Crypto 200
1,517.00 +162.58 (+12.00%)
BYSI May 2024 5.000 put
| Previous close | 2.4000 |
| Open | 2.1700 |
| Bid | 0.3000 |
| Ask | 4.7000 |
| Strike | 5.00 |
| Expiry date | 2024-05-17 |
| Day's range | 2.1700 - 2.1700 |
| Contract range | N/A |
| Volume | |
| Open interest | 1 |
GlobeNewswireBeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics
FLORHAM PARK, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that it hosted a virtual Research and Development (R&D) Day to discuss its lead asset Plinabulin, a dendritic cell (DC) maturation agent, in drug combinations to potentially address the current unmet medical needs in cancer indications where patients failed prio
- GlobeNewswire
BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics
FLORHAM PARK, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced it will host a Research and Development (R&D) Day to discuss the current unmet medical needs and the potential of Plinabulin as a novel immunochemotherapeutic in drug combinations and updates for SEED Therapeutics on Wednesday, May 15th, 2024 at 10:00 a.m. ET. T
- GlobeNewswire
BeyondSpring Files 2023 Annual Report on Form 20-F
FLORHAM PARK, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the U.S. Securities and Exchange Commission (“SEC”) on April 29, 2024. The annual report on Form 20-F, which contains the Company’s audited consolidated financial
